Business
Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results
Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the
About this update from Context Therapeutics Inc.
[{"type":"text","content":"Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data presented at AACR Annual Meeting showcased potential of ONA-XR and CLDN6xCD3 bispecific development program PHILADELPHIA, May 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced financial results for the first quarter ended March 31, 2022, and highlighted recent corporate accomplishments. “During the first quarter, Context laid a strong foundation upon which to build. Encouraging data was presented from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone extended release (ONA-XR), the company’s lead clinical program, at the Association for Cancer Research (AACR) Annual Meeting 2022. The preclinical data for ONA-XR highlight the breadth of its potential as a highly promising combination agent with standard-of-care therapies, as well as with emerging therapies for hormone positive tumors such as immune checkpoint inhibitors and inhibitors of the AURKA/STAT3 oncogenic axis. Additionally at AACR, two poster presentations for our Claudin 6 x CD3 (“CLDN6xCD3”) bispecific antibody program highlighted the program’s selectivity and potency. We also announced that an abstract on the results of the monotherapy portion of our ongoing Phase 2 trial of ONA-XR in granulosa cell tumors of the ovary was accepted for oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,” said Martin Lehr, CEO of Context Therapeutics. “Looking ahead, 2022 looks to be a pivotal year for Context. We anticipate reporting preliminary data of ONA-XR from ongoing Phase 2 trials in breast, ovarian, and endometrial cancers later this year. The Company will also select a development candidate for our CLDN6xCD3 program by year-end. We are excited by the potential of our pipeline to make a difference in the treatment of female cancers.” First Quarter 2022 and Recent Corporate Highlights Pipeline Updates In May 2022, announced an abstract on the results of the monotherapy portion of an ongoing Phase 2 trial...